Global Information
회사소개 | 문의 | 비교리스트

세계의 기관지경련 시장(2021-2028년)

Global Bronchial Spasm Market - 2021-2028

리서치사 DataM Intelligence
발행일 On Demand Report 상품코드 1043594
페이지 정보 영문 180 Pages 배송안내 2일 (영업일 기준)
가격
US $ 4,350 ₩ 5,542,000 PDF & Excel (Single User License)
US $ 4,850 ₩ 6,179,000 PDF & Excel (Multiple User License)
US $ 7,850 ₩ 10,002,000 PDF & Excel (Enterprise License)


세계의 기관지경련 시장(2021-2028년) Global Bronchial Spasm Market - 2021-2028
발행일 : On Demand Report 페이지 정보 : 영문 180 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

기관지경련은 기관지벽의 근육이 돌연 수축하는 것으로, 기관지연축이라고도 불립니다. 경증부터 중증까지의 호흡 곤란을 일으킵니다.

세계의 기관지경련(Bronchial Spasm) 시장에 대해 조사 분석했으며, 업계 분석, 부문별 시장 분석, 경쟁 상황, 주요 기업 등에 대한 체계적인 정보를 제공합니다.

목차

제1장 세계의 기관지경련 시장 - 조사 방법과 범위

제2장 세계의 기관지경련 시장 - 시장 정의와 개요

제3장 세계의 기관지경련 시장 - 주요 요약

제4장 세계의 기관지경련 시장 - 시장 역학

  • 시장에 영향을 미치는 요인
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
    • 영향 분석

제5장 세계의 기관지경련 시장 - 업계 분석

  • Porter's Five Forces 분석
  • 파이프라인 분석
  • 역학
  • 공급망 분석
  • 가격 분석
  • 규제 분석
  • 미충족 수요

제6장 세계의 기관지경련 시장 - COVID-19 분석

  • 시장에 대한 COVID-19의 분석
  • COVID-19에서의 가격 동향
  • 수급 스펙트럼
  • 팬데믹 동안 시장과 관련된 정부 정책
  • 제조업체의 전략적 이니셔티브
  • 결론

제7장 세계의 기관지경련 시장 - 치료별

  • 서론
  • 투약
  • 단시간 작용형 기관지확장제
  • 장시간 작용형 기관지확장제
  • 흡입 스테로이드
  • 경구/정맥내 스테로이드
  • 진단

제8장 세계의 기관지경련 시장 - 원인별

  • 서론
  • 천식
  • 만성폐쇄성폐질환(COPD)
  • 폐기종
  • 만성 기관지염
  • 바이러스, 세균, 진균에 의한 폐감염증
  • 대기오염/스모크
  • 애완동물 비듬, 화분, 곰팡이, 먼지 등의 환경 알레르겐
  • 세정제나 제조 공정에서 사용되는 화학제품의 매연
  • 전신 마취(주로 기도 자극의 원인이 되는 것)
  • 항응혈약
  • 항생물질

제9장 세계의 기관지경련 시장 - 치료 판매별

  • 서론
  • 최종사용자
  • 유통 채널

제10장 세계의 기관지경련 시장 - 지역별

  • 서론
  • 북미
  • 유럽
  • 남미
  • 아시아태평양
  • 중동 및 아프리카

제11장 세계의 기관지경련 시장 - 경쟁 상황

  • 주요 발전과 전략
  • 기업 점유율 분석
  • 제품 벤치마크
  • 주목해야 할 주요 기업
  • 파괴적 기술을 보유한 기업
  • 스타트업 기업

제12장 세계의 기관지경련 시장 - 기업 개요

  • Novartis AG
  • GlaxoSmithKline Plc
  • Merck Sharp & Dohme Corp
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceuticals USA, Inc
  • Viatris Inc
  • Sunovion Pharmaceuticals Inc

제13장 세계의 기관지경련 시장 - DataM

KSM 22.01.25

Market Overview

The global bronchial spasm market size was worth US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Bronchial Spasms, also known as Bronchospasm, is a sudden contraction of muscles in the walls of the bronchioles. It is caused by the release (degranulation) of substances from mast cells or basophils under the influence of anaphylatoxins. It causes the difficulty in breathing which ranges from mild to severe.

Market Dynamics

The global bronchial spasm market growth is driven by the increase in incidence and prevalence of asthma and COPD, technological advancements and growing chronic lung disease (including emphysema and chronic bronchitis), anaphylactic shock, or an allergic reaction to chemicals.

Increasing technological advancements is expected to drive the growth in the forecast period

The advanced technological requirement in healthcare products is one of the drivers of this market. Currently, technology is getting way more advanced than traditional techniques. In pulmonary diseases, many people are still unaware of its symptoms. However, according to the World Health Organization (WHO), the current affected people of asthma are around 235 million worldwide. Due to a lack of awareness about asthma and COPD, leading to the increasing number of incidences of these diseases and driving the demand for smart inhalers. Smart inhalers can be connected to multiple devices to take the patients' health updates daily, especially for respiratory conditions like asthma and COPD. It has sensors that remind about the daily dosage and how much it can take. As technology is getting smarter, it's getting useful in healthcare products. However, for people using different medications to control bronchospasms, it also provides multi meditational permissions for them. Smart inhalers are one of the examples of smart technology. Now, for patients suffering from bronchospasm, it is helpful to poise their dosage. Generally, bronchospasm usually starts with inhaled medications known as short-acting beta2-agonists.

In addition, the rising adoption of IoT devices in healthcare is also expected to supplement the market growth. Population and pollution are two main factors which are rapidly growing. With the increasing population, several diseases are coming to know. Some can be diagnosed within a few days, and some can be diagnosed for a limited period. For instance, bronchospasm is a chronic disease, and it is not for a limited period. It affects people for life long. This disease blocks the lines from which the air flows in the body.

Major side effects associated with the bronchodilators is likely to hamper the market growth

On the contrary, side effects related to bronchodilators trembling, particularly in the hands, nervous tension, headaches, suddenly noticeable heartbeats (palpitations), muscle cramps, a dry mouth, constipation and cough are are likely to hamper the market growth.

COVID-19 Impact Analysis

According to a research study by Jose Luis Izquierdo et al., published in European Respiratory Journal, March 2021, the study results found that allergy-related factors such as rhinitis and eczema were less common in asthmatic patients with COVID-19. There is a high prevalence of these comorbidities observed in patients with COVID-19 who required hospital admission. Furthermore, the use of inhaled corticosteroids (ICS) was lower in patients who required hospitalization due to COVID-19 than non-hospitalized patients (48.3% versus 61.5%). Although patients treated with biologics showed increased severity and more comorbidities at the ear, nose, and throat level, COVID-19-related hospitalizations in these patients were relatively low (0.23%). Thus, patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors. Inhaled corticosteroids (ICS) and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection.

Segment Analysis

The short-acting beta2-agonists segment is expected to hold the largest share in this market segment

Short-acting beta2-agonists (SABA) are a type of bronchodilator. These are the most common immediate-relief drugs for treating asthma attacks and managing acute and stable exacerbations of chronic obstructive pulmonary disease (COPD). Treatment of bronchospasm usually starts with inhaled medications known as short-acting beta2-agonists. Ventolin or Proventil (albuterol) are common medications used for difficulty breathing or shortness of breath. Albuterol helps to open up the airways. Salbutamol is the most commonly prescribed short-acting beta2-agonists (SABA) and is available under different brand names such as Salamol, Ventolin, and Proventil. The usage of short-acting beta-2-agonists SABAs regularly for at least seven days in stable COPD is associated with the decrease in breathlessness and improvement in post-bronchodilator lung function within 5 minutes. The inhaled form of the drug is available in metered-dose inhalers and as a liquid for compressor-driven nebulizers. Short-acting beta2-agonists (SABA) are utilized to treat symptoms in intermittent asthma, prevent asthma symptoms before exercise, and provide quick relief of symptoms during asthma attacks. A combination of ipratropium and short-acting beta2-agonists (SABA) in severe, acute asthma episodes improves lung function and fewer hospital visits.

Geographical Analysis

North America region holds the largest market share of global bronchial spasm market

North America region is expected to dominate the bronchial spasm market during the forecast period. This growth can be attributed to the rising incidence of diseases such as COPD and asthma, the aging population, increasing research and development activities, and the presence of key market players.

In the United States, asthma is more common in adult women than adult men. According to the Centers for Disease Control and Prevention 2020 report, in the United States, approximately 25 million Americans have asthma. This equals about 1 in 13 Americans, including 8 percent of adults and 7 percent of children. About 20 million U.S. adults age 18 and over have asthma. Similarly, asthma is a significant public health concern in Canada. As a lifelong respiratory illness, asthma affects the work productivity, quality of life, mental health, and psychological wellbeing of the Canadian population. In Canada, over 3.8 million individuals had asthma in 2019, as per asthma Canada's 2019 annual asthma survey report. The high number of patients affected by asthma increases the demand for drugs to treat target disease, thereby boosting the growth of this region.

Moreover, the rise in the number of initiatives undertaken by government and non-government organizations is increasing the overall revenue. For instance, CDC's National Asthma Control Program (NACP) provides funds for educating asthma-affected patients. Such initiatives are likely to raise awareness about asthma, which will increase the adoption of drugs in the treatment of asthma, leading to verticle growth.

Competitive Landscape

The global bronchial spasm market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include GlaxoSmithKline Plc, Merck Sharp & Dohme Corp, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceuticals USA, Inc, Viatris Inc and Sunovion Pharmaceuticals Inc.

Global Bronchial Spasm Market - Key Companies to Watch

Novartis AG

Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, established in 1996. The company has over 105,794 employees and operates business through two divisions: Innovative medicine, Sandoz. Made up of two business units- Novartis Pharmaceuticals, which includes Novartis Gene Therapies, and Novartis Oncology - our Innovative Medicines Division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people worldwide access high-quality medicines.

Product Portfolio: Seebri Breezhaler (Glycopyrronium)- Seebri capsules for inhalation contain the active ingredient, glycopyrronium bromide (glycopyrrolate) in a capsule form. The capsules are for oral inhalation only. The powder from the capsule is inhaled (breathed into the lungs), using the Breezhaler inhalation device provided with the medicine.

Why Purchase the Report?

  • Visualize the composition of the bronchial spasm market segmentation by treatment, cause, treatment sales and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in bronchial spasm market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of bronchial spasm market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players.

The global bronchial spasm market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Bronchial Spasm Market - By Treatment

  • Medications

Short-acting bronchodilators

  • Albuterol (AccuNeb, Proventil HFA, ProAir HFA, Ventolin HFA)
  • Levalbuterol (Xopenex, Xopenex HFA)

Long-acting bronchodilators

  • Aclidinium (Tudorza)
  • Arformoterol (Brovana)
  • Formoterol (Foradil, Perforomist)
  • Glycopyrrolate (Seebri Neohaler)
  • Indacaterol (Arcapta)
  • Olodaterol (Striverdi Respimat)
  • Salmeterol (Serevent)
  • Tiotropium (Spiriva)

Inhaled steroids

  • Salbutamol

Oral or intravenous steroids

  • Diagnosis

Spirometry

Lung diffusion and Lung volume tests

Pulse oximetry tests

Arterial blood gas tests

Chest X-ray

Computed tomography (CT) scans

Global Bronchial Spasm Market - By Cause

  • Asthma
  • Chronic Obstructive Pulmonary Disorder (COPD)
  • Emphysema
  • Chronic Bronchitis
  • Viral, Bacteria, And Fungal Lung Infections
  • Blood-Thinning Medications
  • Antibiotics
  • Others

Global Bronchial Spasm Market - By Treatment Sales

  • End-Users

Hospitals

Diagnostic Centers

Clinics

Others

  • Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Bronchial Spasm Market - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • South America

Table of Contents

1. Global Bronchial Spasm Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Bronchial Spasm Market - Market Definition and Overview

3. Global Bronchial Spasm Market - Executive Summary

  • 3.1. Market Snippet by Treatment
  • 3.2. Market Snippet by Cause
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Bronchial Spasm Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. Major side effects associated with the bronchodilators
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Bronchial Spasm Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Epidemiology
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs

6. Global Bronchial Spasm Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Bronchial Spasm Market - By Treatment

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 7.1.2. Market Attractiveness Index, By Treatment
  • 7.2. Medications*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Short-acting bronchodilators
      • 7.3.1.1. Albuterol (AccuNeb, Proventil HFA, ProAir HFA, Ventolin HFA)
      • 7.3.1.2. Levalbuterol (Xopenex, Xopenex HFA)
  • 7.4. Long-acting bronchodilators
      • 7.4.1.1. Aclidinium (Tudorza)
      • 7.4.1.2. Arformoterol (Brovana)
      • 7.4.1.3. Formoterol (Foradil, Perforomist)
      • 7.4.1.4. Glycopyrrolate (Seebri Neohaler)
      • 7.4.1.5. Indacaterol (Arcapta)
      • 7.4.1.6. Olodaterol (Striverdi Respimat)
      • 7.4.1.7. Salmeterol (Serevent)
      • 7.4.1.8. Tiotropium (Spiriva)
  • 7.5. Inhaled steroids
      • 7.5.1.1. Salbutamol
  • 7.6. Oral or intravenous steroids
  • 7.7. Diagnosis
      • 7.7.1.1. Spirometry
      • 7.7.1.2. Lung diffusion and Lung volume tests
      • 7.7.1.3. Pulse oximetry tests
      • 7.7.1.4. Arterial blood gas tests
      • 7.7.1.5. Chest X-ray
      • 7.7.1.6. Computed tomography (CT) scans

8. Global Bronchial Spasm Market - By Cause

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 8.1.2. Market Attractiveness Index, By Cause
  • 8.2. Asthma*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Chronic Obstructive Pulmonary Disorder (COPD)
  • 8.4. Emphysema
  • 8.5. Chronic Bronchitis
  • 8.6. Viral, Bacteria, And Fungal Lung Infections
  • 8.7. Air Pollution or Smoke
  • 8.8. Environmental Allergens, Such as Pet Dander, Pollen, Mold, And Dust
  • 8.9. Fumes From Chemicals Used in Cleaning Products and Manufacturing
  • 8.10. General Anesthesia, Mostly Causing Airway Irritation
  • 8.11. Blood-Thinning Medications
  • 8.12. Antibiotics

9. Global Bronchial Spasm Market - By Treatment Sales

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 9.1.2. Market Attractiveness Index, By Treatment Sales
  • 9.2. End-User*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    • 9.2.3. Hospitals
    • 9.2.4. Diagnostic Centers
    • 9.2.5. Clinics
    • 9.2.6. Others
  • 9.3. Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies

10. Global Bronchial Spasm Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales

11. Global Bronchial Spasm Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch
  • 11.5. Company with disruptive technology
  • 11.6. Start-Up Companies

12. Global Bronchial Spasm Market- Company Profiles

  • 12.1. Novartis AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GlaxoSmithKline Plc
  • 12.3. Merck Sharp & Dohme Corp
  • 12.4. AstraZeneca plc
  • 12.5. Boehringer Ingelheim International GmbH
  • 12.6. Teva Pharmaceuticals USA, Inc
  • 12.7. Viatris Inc
  • 12.8. Sunovion Pharmaceuticals Inc

LIST NOT EXHAUSTIVE

13. Global Bronchial Spasm Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us
Back to Top
전화 문의
F A Q